Department of Clinical Immunology, University Hospital Alexandrovska, Medical University Sofia, Sofia, Bulgaria.
Department of Genetics, St. Kliment Ohridski University, Sofia, Bulgaria.
Int J Immunogenet. 2021 Apr;48(2):193-200. doi: 10.1111/iji.12517. Epub 2020 Oct 28.
The implementation of the immune checkpoint blockade as a therapeutic option in contemporary oncology is one of the significant immunological achievements in the last century. Constantly accumulating evidence suggests that the response to immune checkpoint inhibitors (ICIs) is not universal. Therefore, it is critical to identify determinants for response, resistance and adverse effects of immune checkpoint therapy that could be developed as prognostic and predictive markers. Recent large scale analyses of cancer genome data revealed the key role of HLA class I and class II molecules in cancer immunoediting, and it appears that HLA diversity can predict response to ICIs. In the present review, we summarize the emerging data on the role of HLA germline variations as a marker for response to ICIs.
免疫检查点阻断作为当代肿瘤学的一种治疗选择，是上个世纪免疫学的重大成就之一。不断积累的证据表明，免疫检查点抑制剂（ICIs）的反应并非普遍存在。因此，确定免疫检查点治疗的反应、耐药性和不良反应的决定因素至关重要，这些因素可以作为预后和预测标志物进行开发。最近对癌症基因组数据的大规模分析揭示了 HLA Ⅰ类和Ⅱ类分子在癌症免疫编辑中的关键作用，并且 HLA 多样性似乎可以预测对 ICI 的反应。在本综述中，我们总结了 HLA 种系变异作为对 ICI 反应的标志物的新兴数据。
